No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Raises Target Price to $43
Agios Pharmaceuticals Price Target Maintained With a $58.00/Share by HC Wainwright & Co.
Agios Pharmaceuticals Analyst Ratings
H.C. Wainwright Initiates Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $58